CCKBR and neoplasm: Here, we demonstrate a clinically feasible way for augmented tumor-specific uptake of [177Lu]Lu-PP-F11N by the pharmacological interference with mTORC1 activity, which led to increased CCKBR protein levels in cancer cells, and consequently higher uptake of radiolabeled minigastrin.